GT-20029

GT-20029, also known as AR-PROTAC, is an androgen receptor degradation enhancer which is under development for the treatment of androgenetic alopecia (male-pattern hair loss) and acne.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

GT-20029, also known as AR-PROTAC, is an androgen receptor degradation enhancer which is under development for the treatment of androgenetic alopecia (male-pattern hair loss) and acne. It is used topically in gel form.

The drug acts as an androgen receptor (AR) proteolysis targeting chimera (PROTAC), facilitating the degradation of the AR via enhancement of ubiquitin-mediated proteolysis. It has been found to block the AR-mediated miniaturization of hair follicles in preclinical research. GT-20029 is under development by Suzhou Kintor Pharmaceuticals.

As of September 2024, it is in phase 2 clinical trials and is advancing to phase 3 trials. The chemical structure of GT-20029 does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1315389949 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.